PURPOSE: To investigate the safety and pharmacokinetics of R(+)XK469, a quinoxaline analogue, in patients with advanced refractory solid tumours. Preclinical studies suggested that efficacy was independent of schedule but that toxicity was decreased by dividing the dose. METHODS: R(+)XK469 was initially administered as a 30 min intravenous infusion on days 1-5 of a 21-d cycle. Based on the demonstration of a long half-life, the dosing schedule was subsequently amended to infusion on days 1, 3 and 5 of a 21-d cycle. An alternate single-dose schedule of once every 21 d was also explored. Blood samples were collected for pharmacokinetic studies. RESULTS: Dose-limiting toxicity (DLT) was neutropaenia. There was significant interindividual variability in clearance as evidenced by a coefficient of variation of 46%. A flat-dosing scheme (not based on body surface area) was justified by the absence of correlation between clearance and body surface area. A partial response was observed in a patient with nasopharyngeal carcinoma. CONCLUSIONS: The recommended phase II doses are 850-1100 mg/d on days 1, 3 and 5 of a 21-d cycle and 2500 mg on day 1 of a 21-d cycle. The observed interpatient pharmacokinetic variability should prompt investigation into the presence of genetic polymorphism in relevant metabolizing enzymes.
PURPOSE: To investigate the safety and pharmacokinetics of R(+)XK469, a quinoxaline analogue, in patients with advanced refractory solid tumours. Preclinical studies suggested that efficacy was independent of schedule but that toxicity was decreased by dividing the dose. METHODS: R(+)XK469 was initially administered as a 30 min intravenous infusion on days 1-5 of a 21-d cycle. Based on the demonstration of a long half-life, the dosing schedule was subsequently amended to infusion on days 1, 3 and 5 of a 21-d cycle. An alternate single-dose schedule of once every 21 d was also explored. Blood samples were collected for pharmacokinetic studies. RESULTS: Dose-limiting toxicity (DLT) was neutropaenia. There was significant interindividual variability in clearance as evidenced by a coefficient of variation of 46%. A flat-dosing scheme (not based on body surface area) was justified by the absence of correlation between clearance and body surface area. A partial response was observed in a patient with nasopharyngeal carcinoma. CONCLUSIONS: The recommended phase II doses are 850-1100 mg/d on days 1, 3 and 5 of a 21-d cycle and 2500 mg on day 1 of a 21-d cycle. The observed interpatient pharmacokinetic variability should prompt investigation into the presence of genetic polymorphism in relevant metabolizing enzymes.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: T H Corbett; P LoRusso; L Demchick; C Simpson; S Pugh; K White; J Kushner; L Polin; J Meyer; J Czarnecki; L Heilbrun; J P Horwitz; J L Gross; C H Behrens; B A Harrison; R J McRipley; G Trainor Journal: Invest New Drugs Date: 1998 Impact factor: 3.850
Authors: Ramesh R Boinpally; Sen-Lin Zhou; Patricia M LoRusso; Ralph E Parchment Journal: Cancer Chemother Pharmacol Date: 2004-12-09 Impact factor: 3.333
Authors: Lawrence W Anderson; Jerry M Collins; Raymond W Klecker; Aspandiar G Katki; Ralph E Parchment; Ramesh R Boinpally; Patricia M LoRusso; S Percy Ivy Journal: Cancer Chemother Pharmacol Date: 2005-05-13 Impact factor: 3.333
Authors: R M Snapka; H Gao; D R Grabowski; D Brill; K K Chan; L Li; G C Li; R Ganapathi Journal: Biochem Biophys Res Commun Date: 2001-02-02 Impact factor: 3.575
Authors: Wendy Stock; Samir D Undevia; Carol Bivins; Farhad Ravandi; Olatoyosi Odenike; Stefan Faderl; Elizabeth Rich; Gautam Borthakur; Lucy Godley; Srdan Verstovsek; Andrew Artz; William Wierda; Richard A Larson; Yanming Zhang; Jorge Cortes; Mark J Ratain; Francis J Giles Journal: Invest New Drugs Date: 2008-04-19 Impact factor: 3.850
Authors: Nisha C Kakodkar; Radhika Peddinti; Morris Kletzel; Yufeng Tian; Lisa J Guerrero; Samir D Undevia; David Geary; Alexandre Chlenski; Qiwei Yang; Helen R Salwen; Susan L Cohn Journal: Pediatr Blood Cancer Date: 2011-01 Impact factor: 3.167